ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
NATCO reported Q1 FY27 consolidated revenue of INR 794.4 Cr and PAT of INR 206.5 Cr. Performance was driven by base business growth and a strong flu season at associate Adcock Ingram.
Natco reported a sharp revenue decline due to lower Revlimid contributions, masked by strong growth in Brazil and domestic segments.
Natco Pharma reported Q1 FY27 revenue of INR 7,944 Mn and Net Profit of INR 2,065 Mn. Strategy focuses on high-barrier US formulations and NCE/Cell & Gene therapy investments.
Natco Pharma reported Q4 FY26 revenue of ₹816.9cr and PAT of ₹269cr. The company is diversifying into Brazil, Canada, and South Africa to counter Revlimid decline.
Natco Pharma faces a sharp transition as Revlimid-led super-profits decline, shifting focus to Brazil and Canada. Management guides for a significant 50% profit contraction in FY27 as it attempts to diversify earnings.
Natco Pharma reported FY26 revenue of INR 43,759 Mn and PAT of INR 14,185 Mn, driven by US generic launches and high export formulation contributions.